• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片类药物替代疗法对刑满释放人员降低阿片类药物依赖史者死亡率的成本效益分析。

A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.

作者信息

Gisev Natasa, Shanahan Marian, Weatherburn Don J, Mattick Richard P, Larney Sarah, Burns Lucy, Degenhardt Louisa

机构信息

National Drug and Alcohol Research Centre, UNSW Australia, Sydney, New South Wales, Australia.

New South Wales Bureau of Crime Statistics and Research (BOCSAR), Sydney, New South Wales, Australia.

出版信息

Addiction. 2015 Dec;110(12):1975-84. doi: 10.1111/add.13073. Epub 2015 Sep 23.

DOI:10.1111/add.13073
PMID:26212260
Abstract

AIM

Although opioid substitution therapy (OST) immediately after prison release reduces mortality, the cost-effectiveness of treatment has not been examined. Therefore, we undertook a cost-effectiveness analysis of OST treatment upon prison release and the prevention of death in the first 6 months post-release.

DESIGN

Population-based, retrospective data linkage study using records of OST entrants (1985-2010), charges and court appearances (1993-2011), prison episodes (2000-11) and death notifications (1985-2011).

SETTING

New South Wales, Australia.

PARTICIPANTS

A cohort of 16,073 people with a history of opioid dependence released from prison for the first time between 1 January 2000 and 30 June 2011.

INTERVENTION

OST treatment compared to no OST treatment at prison release.

MEASUREMENTS

Mortality and costs (treatment, criminal justice system-court, penalties, prison-and the social costs of crime) were evaluated at 6 months post-release. Analyses included propensity score matching, bootstrapping and regression.

FINDINGS

A total of 13,468 individuals were matched (6734 in each group). Twenty (0.3%) people released onto OST died, compared with 46 people (0.7%) not released onto OST. The final average costs were lower for the group that received OST post-release ($7206 versus $14,356). The incremental cost-effectiveness ratio showed that OST post-release was dominant, incurring lower costs and saving more lives. The probability that OST post-release is cost-effective per life-year saved is 96.7% at a willingness to pay of $500.

CONCLUSION

Opioid substitution treatment (compared with no such treatment), given on release from prison to people with a history of opioid dependence, is cost-effective in reducing mortality in the first 6 months of release.

摘要

目的

虽然出狱后立即进行阿片类药物替代疗法(OST)可降低死亡率,但该治疗的成本效益尚未得到研究。因此,我们对出狱后进行OST治疗以及预防释放后前6个月内死亡的情况进行了成本效益分析。

设计

基于人群的回顾性数据关联研究,使用OST参与者记录(1985 - 2010年)、收费及出庭记录(1993 - 2011年)、监禁记录(2000 - 11年)和死亡通知(1985 - 2011年)。

地点

澳大利亚新南威尔士州。

参与者

2000年1月1日至2011年6月30日期间首次从监狱释放的16,073名有阿片类药物依赖史的人群。

干预措施

将出狱时接受OST治疗与未接受OST治疗进行比较。

测量指标

在释放后6个月评估死亡率和成本(治疗、刑事司法系统 - 法庭、处罚、监禁以及犯罪的社会成本)。分析包括倾向得分匹配、自抽样法和回归分析。

研究结果

共匹配了13,468人(每组6734人)。接受OST治疗的释放者中有20人(0.3%)死亡,未接受OST治疗的有46人(0.7%)死亡。释放后接受OST治疗组的最终平均成本较低(7206美元对14,356美元)。增量成本效益比表明,释放后进行OST治疗具有优势,成本更低且挽救了更多生命。在支付意愿为500美元时,释放后进行OST治疗每挽救一个生命年具有成本效益的概率为96.7%。

结论

对于有阿片类药物依赖史的人,出狱时给予阿片类药物替代治疗(与不进行此类治疗相比)在降低释放后前6个月的死亡率方面具有成本效益。

相似文献

1
A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.阿片类药物替代疗法对刑满释放人员降低阿片类药物依赖史者死亡率的成本效益分析。
Addiction. 2015 Dec;110(12):1975-84. doi: 10.1111/add.13073. Epub 2015 Sep 23.
2
The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study.出狱后阿片类药物替代疗法对死亡率的影响:回顾性数据链接研究。
Addiction. 2014 Aug;109(8):1306-17. doi: 10.1111/add.12536. Epub 2014 Apr 14.
3
Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.阿片类药物替代疗法在阿片类药物使用障碍治疗中的应用:一项英国成本效益建模研究的结果
J Med Econ. 2017 Jul;20(7):740-748. doi: 10.1080/13696998.2017.1325744. Epub 2017 May 25.
4
Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.监狱内阿片类药物替代治疗和释放后治疗保留对再监禁风险的影响。
Addiction. 2012 Feb;107(2):372-80. doi: 10.1111/j.1360-0443.2011.03618.x. Epub 2011 Oct 26.
5
Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England.在监狱接受阿片类药物替代治疗能否降低释放后死亡风险?一项在英格兰开展的全国性前瞻性观察研究。
Addiction. 2017 Aug;112(8):1408-1418. doi: 10.1111/add.13779. Epub 2017 Mar 1.
6
Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.审前羁押中的阿片类药物替代治疗:来自瑞士日内瓦的案例研究。
Swiss Med Wkly. 2013 Nov 1;143:w13898. doi: 10.4414/smw.2013.13898. eCollection 2013.
7
A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.澳大利亚新南威尔士州监狱中寻求和停止阿片类药物替代治疗的原因的定性研究。
Drug Alcohol Rev. 2017 May;36(3):305-310. doi: 10.1111/dar.12442. Epub 2016 Jun 21.
8
A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.澳大利亚新南威尔士州美沙酮和丁丙诺啡维持治疗阿片类药物依赖的纵向比较。
Addiction. 2015 Apr;110(4):646-55. doi: 10.1111/add.12834.
9
A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women.阿片类药物依赖男性和女性中阿片类药物替代疗法使用情况的比较研究。
Drug Alcohol Rev. 2014 Sep;33(5):499-505. doi: 10.1111/dar.12151. Epub 2014 May 20.
10
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.与美沙酮维持治疗和丁丙诺啡维持治疗相比,注射用长效纳曲酮治疗阿片类药物依赖的成本效益分析
Subst Abus. 2015;36(2):226-31. doi: 10.1080/08897077.2015.1010031. Epub 2015 Mar 16.

引用本文的文献

1
Psychiatric disorders and mental health care among incarcerated men: A prerelease cross-sectional study in France.法国在押男性中的精神疾病与心理健康护理:一项释放前横断面研究
Eur Psychiatry. 2025 Apr 2;68(1):e66. doi: 10.1192/j.eurpsy.2025.2443.
2
Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.社区药房中阿片类药物使用障碍治疗扩展的研究重点。
Subst Abus. 2023 Oct;44(4):264-276. doi: 10.1177/08897077231203849. Epub 2023 Oct 30.
3
Modeling as Visioning: Exploring the Impact of Criminal Justice Reform on Health of Populations with Substance Use Disorders.
建模即展望:探究刑事司法改革对患有物质使用障碍人群健康的影响。
MDM Policy Pract. 2023 Oct 11;8(2):23814683231202984. doi: 10.1177/23814683231202984. eCollection 2023 Jul-Dec.
4
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.丁丙诺啡药物用于治疗阿片类物质使用障碍的发现、研发及美国食品药品监督管理局批准历程。
Drug Alcohol Depend Rep. 2023 Jan 10;6:100133. doi: 10.1016/j.dadr.2023.100133. eCollection 2023 Mar.
5
Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.在监禁的阿片类药物使用障碍者从监狱释放之前和之后,使用延长释放注射用纳曲酮的成本效益。
J Subst Abuse Treat. 2022 Oct;141:108835. doi: 10.1016/j.jsat.2022.108835. Epub 2022 Jul 2.
6
Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.调查阿片类激动剂治疗中患者剂量费用的成本和影响:对澳大利亚治疗患者的横断面调查结果。
Drug Alcohol Rev. 2022 May;41(4):841-850. doi: 10.1111/dar.13437. Epub 2022 Feb 7.
7
Service Needs for Corrections-Involved Parents With a History of Problematic Opioid Use: A Community Needs Assessment.对有阿片类药物使用问题史的涉惩父母的服务需求:一项社区需求评估。
Front Psychol. 2021 Oct 21;12:667389. doi: 10.3389/fpsyg.2021.667389. eCollection 2021.
8
A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.一项针对 Veterans Health Administration 中涉及法律问题的退伍军人中阿片类药物使用障碍药物治疗的障碍和促进因素的全国性调查。
Subst Abus. 2022;43(1):556-563. doi: 10.1080/08897077.2021.1975867. Epub 2021 Sep 29.
9
Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review.药物治疗阿片类药物使用障碍的经济学评价:系统文献回顾。
Value Health. 2021 Jul;24(7):1068-1083. doi: 10.1016/j.jval.2020.12.023. Epub 2021 May 8.
10
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.在羁押环境中使用长效丁丙诺啡(CAM2038)治疗阿片类药物依赖。
Addiction. 2022 Feb;117(2):382-391. doi: 10.1111/add.15627. Epub 2021 Jul 16.